The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease
Open accessAbstract
Resveratrol, a polyphenol found in red wine, peanuts, soy beans, and pomegranates, possesses a wide range of biological effects. Since resveratrol’s properties seem ideal for treating neurodegenerative diseases, its ability to diminish amyloid plaques was tested. Mice were fed clinically feasible dosages of resveratrol for forty-five days. Neither resveratrol nor its conjugated metabolites were detectable in brain. Nevertheless, resveratrol diminished plaque formation in a region specific manner. The largest reductions in the percent area occupied by plaques were observed in medial cortex (−48%), striatum (−89%) and hypothalamus (−90%). The changes occurred without detectable activation of SIRT-1 or alterations in APP processing. However, brain glutathione declined 21% and brain cysteine increased 54%. The increased cysteine and decreased glutathione may be linked to the diminished plaque formation. This study supports the concept that onset of neurodegenerative disease may be delayed or mitigated with use of dietary chemo-preventive agents that protect against β-amyloid induced neuronal damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondria, Oxidants, and Aging
Balaban, R. S., Nemoto, S., & Finkel, T. (2005) · Cell · doi:10.1016/j.cell.2005.02.001 · Cited by 4,388
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057 · cited 9×
“2007.12.013 Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, Puigserver P, Sinclair DA, Tsai LH. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis.”
BackgroundInfluentialA Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447 · cited 1×
“A bioavailable Cu/Zn chelator decreases brain amyloid-β deposition by 49% (Cherny et al., 2001).”
BackgroundExcess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease.
Smith, C. D., Carney, J. M., Starke-Reed, P. E., Oliver, C. N., Stadtman, E. R., Floyd, R. A., & Markesbery, W. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10540 · Cited by 1,296 · cited 1×
“Plausible mechanisms link elevated ROS to the AD-related changes in amyloid, tau and energy metabolism (Mark et al., 1997; Pappolla et al., 1998; Pratico, 2002; Smith et al., 1991).”
BackgroundHensley, K., Carney, J. M., Mattson, M. P., Aksenova, M., Harris, M., Wu, J. F., Floyd, R. A., & Butterfield, D. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3270 · Cited by 1,086
Dietary Intake of Antioxidants and Risk of Alzheimer Disease
Engelhart, M. J. (2002) · JAMA · doi:10.1001/jama.287.24.3223 · Cited by 1,080
Kim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sananbenesi, F., Rodgers, J. T., Delalle, I., Baur, J. A., Sui, G., Armour, S. M., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601758 · Cited by 1,074
Mitochondria take center stage in aging and neurodegeneration
Beal, M. F. (2005) · Annals of Neurology · doi:10.1002/ana.20624 · Cited by 957
Self-citation
Cited by
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
Turner, R. S., Thomas, R. G., Craft, S., van Dyck, C. H., Mintzer, J., Reynolds, B. A., Brewer, J. B., Rissman, R. A., Raman, R., Aisen, P. S., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002035 · Cited by 736
Kennedy, D. O., & Wightman, E. L. (2011) · Advances in Nutrition · doi:10.3945/an.110.000117 · Cited by 684
Vingtdeux, V., Giliberto, L., Zhao, H., Chandakkar, P., Wu, Q., Simon, J. E., Janle, E. M., Lobo, J., Ferruzzi, M. G., Davies, P., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.060061 · Cited by 645
Small molecule SIRT1 activators for the treatment of aging and age-related diseases
Hubbard, B. P., & Sinclair, D. A. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.12.004 · Cited by 569
SIRT1 in Neurodevelopment and Brain Senescence
Herskovits, A. Z., & Guarente, L. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.028 · Cited by 488
Resveratrol: French Paradox Revisited
Catalgol, B., Batirel, S., Taga, Y., & Ozer, N. K. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00141 · Cited by 449
“The largest reductions in the percent area occupied by plaques were observed in medial cortex (−48%), striatum (−89%), and hypothalamus (−90%; Karuppagounder et al., 2009).”
BackgroundBrain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
M. de la Monte, S. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 448
What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol
Vang, O., Ahmad, N., Baile, C. A., Baur, J. A., Brown, K., Csiszar, A., Das, D. K., Delmas, D., Gottfried, C., Lin, H.-Y., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019881 · Cited by 437
Capiralla, H., Vingtdeux, V., Zhao, H., Sankowski, R., Al‐Abed, Y., Davies, P., & Marambaud, P. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07594.x · Cited by 426
Mitochondrial Diseases of the Brain
Chaturvedi, R. K., & Flint Beal, M. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.018 · Cited by 413
Neuroprotective Mechanisms of Resveratrol in Alzheimer’s Disease: Role of SIRT1
Gomes, B. A. Q., Silva, J. P. B., Romeiro, C. F. R., dos Santos, S. M., Rodrigues, C. A., Gonçalves, P. R., Sakai, J. T., Mendes, P. F. S., Varela, E. L. P., & Monteiro, M. C. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/8152373 · Cited by 403
Neuroprotective action of resveratrol
Bastianetto, S., Ménard, C., & Quirion, R. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.09.011 · Cited by 407
Natural products as a source of Alzheimer's drug leads
Williams, P., Sorribas, A., & Howes, M.-J. R. (2011) · Nat. Prod. Rep. · doi:10.1039/c0np00027b · Cited by 404
Adherence to a Mediterranean-type dietary pattern and cognitive decline in a community population
Tangney, C. C., Kwasny, M. J., Li, H., Wilson, R. S., Evans, D. A., & Morris, M. C. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.007369 · Cited by 397
Review on Alzheimer’s Disease: Inhibition of Amyloid Beta and Tau Tangle Formation
Ashrafian, H., Zadeh, E. H., & Khan, R. H. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.11.192 · Cited by 368
Bioactive compounds in wine: Resveratrol, hydroxytyrosol and melatonin: A review
Fernández-Mar, M. I., Mateos, R., García-Parrilla, M. C., Puertas, B., & Cantos-Villar, E. (2012) · Food Chemistry · doi:10.1016/j.foodchem.2011.08.023 · Cited by 347
Sirtuins Link Inflammation and Metabolism
Vachharajani, V. T., Liu, T., Wang, X., Hoth, J. J., Yoza, B. K., & McCall, C. E. (2016) · Journal of Immunology Research · doi:10.1155/2016/8167273 · Cited by 320
Choi, D.-Y., Lee, Y.-J., Hong, J. T., & Lee, H.-J. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.11.014 · Cited by 305
Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation
Feng, Y., Wang, X.-P., Yang, S.-G., Wang, Y.-J., Zhang, X., Du, X.-T., Sun, X.-X., Zhao, M., Huang, L., & Liu, R.-T. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.08.013 · Cited by 295
Lifespan and healthspan extension by resveratrol
Bhullar, K. S., & Hubbard, B. P. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.01.012 · Cited by 274
Natural polyphenols against neurodegenerative disorders: Potentials and pitfalls
Ebrahimi, A., & Schluesener, H. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.01.006 · Cited by 270
Dietary resveratrol prevents Alzheimer’s markers and increases life span in SAMP8
Porquet, D., Casadesús, G., Bayod, S., Vicente, A., Canudas, A. M., Vilaplana, J., Pelegrí, C., Sanfeliu, C., Camins, A., Pallàs, M., et al. (2013) · AGE · doi:10.1007/s11357-012-9489-4 · Cited by 262
Resveratrol: review on therapeutic potential and recent advances in drug delivery
Pangeni, R., Sahni, J. K., Ali, J., Sharma, S., & Baboota, S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.919253 · Cited by 255
Andrade, S., Ramalho, M. J., Loureiro, J. A., & Pereira, M. D. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092313 · Cited by 240
Vitamin B1 (thiamine) and dementia
Gibson, G. E., Hirsch, J. A., Fonzetti, P., Jordan, B. D., Cirio, R. T., & Elder, J. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13031 · Cited by 214
Self-citationProtective effects and mechanisms of sirtuins in the nervous system
Zhang, F., Wang, S., Gan, L., Vosler, P. S., Gao, Y., Zigmond, M. J., & Chen, J. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.001 · Cited by 211
Griñán-Ferré, C., Bellver-Sanchis, A., Izquierdo, V., Corpas, R., Roig-Soriano, J., Chillón, M., Andres-Lacueva, C., Somogyvári, M., Sőti, C., Sanfeliu, C., et al. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101271 · Cited by 208
Antioxidant Effects of Resveratrol in Cardiovascular, Cerebral and Metabolic Diseases
Carrizzo, A., Forte, M., Damato, A., Trimarco, V., Salzano, F., Bartolo, M., Maciag, A., Puca, A. A., & Vecchione, C. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.07.021 · Cited by 203
Resveratrol as a calorie restriction mimetic: therapeutic implications
Chung, J. H., Manganiello, V., & Dyck, J. R. B. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2012.07.004 · Cited by 192
Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment
Andrade, S., Ramalho, M. J., Pereira, M. D. C., & Loureiro, J. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01261 · Cited by 173
Frozza, R. L., Bernardi, A., Hoppe, J. B., Meneghetti, A. B., Matté, A., Battastini, A. M. O., Pohlmann, A. R., Guterres, S. S., & Salbego, C. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8401-2 · Cited by 165
“Taking into account our results, a concern about the efficacy of resveratrol as an anti-Aβ drug remains to be determined; however, some studies have shown that resveratrol may binding to different assemblies of Aβ [75] and selectively remodels soluble oligomers and fibrils of Aβ [76], reduces plaque pathology in trans…”
ResultTurn up the power - pharmacological activation of mitochondrial biogenesis in mouse models
Komen, J. C., & Thorburn, D. R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12413 · Cited by 149
“…Prevention of cardiomyopathy and cardiac function ND Kuno et al. (2013) Tg19959 mouse model of AD Diminished plaque formation in specific brain areas ND Karuppagounder et al. (2009) APP/PS1 mouse model of AD Diminished plaque formation in specific brain areas ND Vingtdeux et al. (2010) N171-82Q…”
BackgroundKatsouri, L., Lim, Y. M., Blondrath, K., Eleftheriadou, I., Lombardero, L., Birch, A. M., Mirzaei, N., Irvine, E. E., Mazarakis, N. D., & Sastre, M. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606171113 · Cited by 146
A Mitocentric View of Alzheimer's Disease Suggests Multi-Faceted Treatments
Gibson, G. E., & Shi, Q. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100336 · Cited by 124
Self-citationCaloric restriction: Beneficial effects on brain aging and Alzheimer’s disease
Van Cauwenberghe, C., Vandendriessche, C., Libert, C., & Vandenbroucke, R. E. (2016) · Mammalian Genome · doi:10.1007/s00335-016-9647-6 · Cited by 121
“Some authors state that resveratrol treatment does not seem to affect APP processing because no changes in the levels of APP cleavage products were observed (Karuppagounder et al. 2009; Porquet et al. 2014).”
BackgroundInfluentialTau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development
Mueed, Z., Tandon, P., Maurya, S. K., Deval, R., Kamal, M. A., & Poddar, N. K. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01017 · Cited by 111
Metabolic effects of resveratrol: Addressing the controversies
Bitterman, J. L., & Chung, J. H. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1808-8 · Cited by 109
“mer’s disease, resveratrol can reduce the accumulation of amyloid b (Ab) peptides in various cell line models [175], and the accumulation of Ab plaques [176].”
Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
Colognesi, M., Gabbia, D., & De Martin, S. (2020) · Biomedicines · doi:10.3390/biomedicines8070229 · Cited by 98
“This study further supports previous evidences on the effect of resveratrol in reducing Aβ plaque formation associated with AD [78].”
ResultNanotechnology to improve the Alzheimer’s disease therapy with natural compounds
Ramalho, M. J., Andrade, S., Loureiro, J. A., & do Carmo Pereira, M. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00694-3 · Cited by 75
Novel strategies for anti-aging drug discovery
Saraswat, K., & Rizvi, S. I. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1349750 · Cited by 66
“Resveratrol is also reported to provide protection against a variety of insults including cardiac failure [118], seizures [119], Parkinson’s disease [120], and Alzheimer’s disease [121].”
BackgroundYang, Y., & Zhang, L. (2020) · Food & Function · doi:10.1039/c9fo02611h · Cited by 57
Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome
D. Hamlett, E., A. Boger, H., Ledreux, A., M. Kelley, C., J. Mufson, E., F. Falangola, M., N. Guilfoyle, D., A. Nixon, R., Patterson, D., Duval, N., et al. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150921095505 · Cited by 46
Oxidative Stress in Alzheimer’s Disease: The Shortcomings of Antioxidant Therapies
Pappolla, M. A., Martins, R. N., Poeggeler, B., Omar, R. A., & Perry, G. (2024) · Journal of Alzheimer's Disease · doi:10.3233/jad-240659 · Cited by 29
Metadata
- Authors
- Karuppagounder, S. S., Pinto, J. T., Xu, H., Chen, H.-L., Beal, M. F., & Gibson, G. E.
- Venue
- Neurochemistry International
- Publisher
- Elsevier BV
- Published
- 2009-02
- Volume
- 54
- Issue
- 2
- Pages
- 111-118
- ISSN
- 0197-0186 (ISSN-L)
- OpenAlex
- W2094789916
- Cited by
- 485
- References
- 61
- FWCI
- 16.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.